Table 2 Comparison of clinical and pathological characteristics of carriers and non-carriers tested at Oslo University Hospital Ullevål (OUH-U)

Below 40 years

5 (38.5%)

24 (5.6%)

Below 50 years

10 (76.9%)

106 (24.8%)

Below 60 years

13 (100%)

222 (52.0%)

 Mean (95% CI)

42 (36.1-47.9)

57.9 (56.8-59.1)

<0.001

 Median (range)

43 (26-58)

58 (23-93)

Predictive test criteria fulfilled

4 (30.8%)

49 (11.5%)

0.035

Stringent NBCG criteria fulfilled

12 (92.3%)

130 (30.4%)

<0.001

TNM

(n = 13)

(n = 422)

 T1

5 (38.5%)

261 (61.8%)

 T2

5 (38.5%)

121 (28.7%)

0.396

 T3

2 (15.3%)

26 (6.2%)

 T4

1 (7.7%)

13 (3.1%)

 N0

8 (61.5%)

295 (72.0%)

 N1

2(15.4%)

82 (19.4%)

0.078

 N2

3(23.1%)

24 (5.7%)

 N3

0

12 (2.8%)

 Distant metastasis

0

2 (0.5%)

0.76

Grade

(n = 13)

(n = 419)

 1

0

101 (24.1%)

0.001

 2

4 (30.8%)

211 (50.4%)

 3

9 (69.2%)

107 (25.5%)

Estrogen receptor status

(n = 13)

(n = 423)

 Positive

7 (53.8%)

371 (87.7%)

<0.001

 Negative

6 (46.2%)

52 (12.3%)

Progesterone receptor status

(n = 13)

(n = 422)

0.045

 Positive

5 (38.5%)

276 (65.4%)

 Negative

8 (61.5%)

146 (34.6%)

HER2 status

(n = 13)

(n = 423)

 Positive

2 (15.4%)

57 (13.5%)

0.84

 Negative

11 (84.6%)

366 (86.5%)

Triple negative breast cancer

(n = 13)

(n = 422)

5 (38.5%)

30 (7.1%)

<0.001

Ki67

(n = 13)

(n = 412)

 Mean (95% CI)

59 (45.3-72.8)

31.3 (29-33)

<0.001

  < 30% activity

11 (84.6%)

182 (44.1%)

0.004